Logo image
Chemotherapy-Induced Atrial Fibrillation With Rapid Ventricular Response in a Patient With Pleomorphic Rhabdomyosarcoma: A Case Report and Approach to Management
Journal article   Open access   Peer reviewed

Chemotherapy-Induced Atrial Fibrillation With Rapid Ventricular Response in a Patient With Pleomorphic Rhabdomyosarcoma: A Case Report and Approach to Management

Mubariz A Hassan, Yashvardhan Batta, Muhammad Adil Afzal and Niyati Grewal
Curēus (Palo Alto, CA), Vol.15(5), e39375
05/23/2023
DOI: 10.7759/cureus.39375
PMCID: PMC10285715
PMID: 37362481
url
https://doi.org/10.7759/cureus.39375View
Published (Version of record) Open Access

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Its prevalence in cancer patients undergoing treatment with radiation or chemotherapeutic agents has been on the rise. The most common offending agents are alkylating agents and anthracyclines causing various types of arrhythmias, including AF. We report a case of a 62-year-old male who was diagnosed with stage IV pleomorphic rhabdomyosarcoma and was started on chemotherapy with a mesna-ifosfamide and doxorubicin (MAI) regimen. He developed AF with a rapid ventricular rate soon after his second cycle of treatment, which got better with the initiation of beta-blocker therapy. Since low blood counts, including low platelet levels, are expected in patients with chemotherapy, the continual use of anticoagulation therapy varies on a case-to-case basis.
Cardiology Internal Medicine Oncology

Details

Metrics

8 Record Views
Logo image